Pulse Biosciences (NASDAQ:PLSE) Stock Price Crosses Above Fifty Day Moving Average – What’s Next?

Pulse Biosciences, Inc (NASDAQ:PLSE) shares crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $16.97 and traded as high as $18.61. Pulse Biosciences shares last traded at $17.95, with a volume of 155,500 shares traded.

Wall Street Analysts Forecast Growth

PLSE has been the subject of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Thursday, January 22nd. Oppenheimer restated an “outperform” rating and issued a $30.00 price objective on shares of Pulse Biosciences in a report on Friday, February 20th. Mizuho set a $30.00 target price on Pulse Biosciences in a report on Friday, February 6th. Finally, Wall Street Zen upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 21st. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $30.00.

Pulse Biosciences Stock Up 2.7%

The firm has a market cap of $1.26 billion, a P/E ratio of -17.20 and a beta of 1.74. The business’s 50 day moving average is $17.11 and its two-hundred day moving average is $16.28.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.06.

Insider Buying and Selling

In other Pulse Biosciences news, insider Kevin Patrick Danahy sold 5,000 shares of Pulse Biosciences stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $23.64, for a total value of $118,200.00. Following the completion of the sale, the insider directly owned 43,298 shares in the company, valued at approximately $1,023,564.72. The trade was a 10.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 85,000 shares of company stock worth $1,994,400 over the last ninety days. Company insiders own 74.60% of the company’s stock.

Institutional Trading of Pulse Biosciences

Several large investors have recently modified their holdings of the stock. Bank of America Corp DE lifted its stake in Pulse Biosciences by 2.7% during the 3rd quarter. Bank of America Corp DE now owns 804,960 shares of the company’s stock valued at $14,248,000 after acquiring an additional 21,424 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Pulse Biosciences by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 499,464 shares of the company’s stock worth $7,538,000 after acquiring an additional 33,744 shares in the last quarter. State Street Corp raised its holdings in shares of Pulse Biosciences by 6.0% in the fourth quarter. State Street Corp now owns 447,067 shares of the company’s stock valued at $6,138,000 after purchasing an additional 25,187 shares during the last quarter. Brooklyn Investment Group raised its holdings in shares of Pulse Biosciences by 330.7% in the fourth quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock valued at $1,844,000 after purchasing an additional 100,081 shares during the last quarter. Finally, Portolan Capital Management LLC bought a new position in shares of Pulse Biosciences during the third quarter valued at about $1,809,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.